ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 102,33
0,13%
Dow Jones
39 264,94
-1,02%
DAX
18 691,32
0,05%
Brent Oil
80,985
-0,67%
Bitcoin
67 949,53
-1,67%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) Actualités

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IBRX
DateHeureSourceTitreSymboleSociété
17/05/202415h00Business WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastNASDAQ:IBRXImmunityBio Inc
09/05/202423h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
07/05/202414h00Business WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®NASDAQ:IBRXImmunityBio Inc
02/05/202422h04Business WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesNASDAQ:IBRXImmunityBio Inc
30/04/202414h00Business WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationNASDAQ:IBRXImmunityBio Inc
25/04/202406h03Business WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerNASDAQ:IBRXImmunityBio Inc
23/04/202403h56Business WireImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:IBRXImmunityBio Inc
06/03/202415h00Business WireNIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral TherapyNASDAQ:IBRXImmunityBio Inc
05/03/202415h00Business WireN-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure StudyNASDAQ:IBRXImmunityBio Inc
26/02/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
24/02/202403h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
21/02/202415h00Business WireImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the TrialNASDAQ:IBRXImmunityBio Inc
05/02/202415h00Business WireImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCGNASDAQ:IBRXImmunityBio Inc
04/01/202403h59Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:IBRXImmunityBio Inc
02/01/202412h00Business WireImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 MillionNASDAQ:IBRXImmunityBio Inc
16/11/202315h00Business WireImmunityBio to Participate in 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:IBRXImmunityBio Inc
07/11/202315h00Business WireFirst Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor ActivityNASDAQ:IBRXImmunityBio Inc
26/10/202318h03Dow Jones NewsImmunityBio Shares Rally as FDA Accepts N-803 ResubmissionNASDAQ:IBRXImmunityBio Inc
26/10/202315h00Business WireFDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA DateNASDAQ:IBRXImmunityBio Inc
23/10/202317h00Dow Jones NewsImmunityBio Shares 11% Higher on License Application Resubmission for N-803NASDAQ:IBRXImmunityBio Inc
23/10/202315h00Business WireImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-SituNASDAQ:IBRXImmunityBio Inc
28/09/202312h06Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:IBRXImmunityBio Inc
22/09/202321h06Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:IBRXImmunityBio Inc
11/09/202312h00Business WireImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant EntitiesNASDAQ:IBRXImmunityBio Inc
29/08/202311h45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ImmunityBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 29, 2023 - (NASDAQ: IBRX)NASDAQ:IBRXImmunityBio Inc
11/08/202311h45PR Newswire (US)IBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio Shareholders of a Lead Plaintiff Deadline of August 29, 2023NASDAQ:IBRXImmunityBio Inc
03/08/202315h00Business WireImmunityBio Names Enrique Diloné as Chief Technology OfficerNASDAQ:IBRXImmunityBio Inc
25/07/202323h02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IBRXImmunityBio Inc
21/07/202302h32Business WireImmunityBio Announces Execution of $40 Million Equity Financing with Institutional InvestorsNASDAQ:IBRXImmunityBio Inc
10/07/202315h30Business WirePhase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer PatientsNASDAQ:IBRXImmunityBio Inc
 Showing the most relevant articles for your search:NASDAQ:IBRX

Dernières Valeurs Consultées

LSE
0E6Q
Lyxor 10y Us Treasury Da...
LSE
CS37
Mitsu Hc Cap 25
LSE
13AD
Hungary 35
BITMOT
809232
Ca Tf 1% St24 Eur
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés